{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Percentage of participants alive and without relapsed disease at two years.","groups":[{"description":"Without LSC, standard cytarabine consolidation\n\nCytarabine consolidation: Cytarabine-based consolidation per institutional standards.","id":"OG000","title":"No Leukemia Stem Cells - Consolidation"},{"description":"LSC present, randomized to cytarabine consolidation\n\nCytarabine consolidation: Cytarabine-based consolidation per institutional standards.","id":"OG001","title":"Leukemia Stem Cells - Consolidation"},{"description":"LSC present, randomized to allogeneic transplant\n\nAllogeneic transplant: Allogeneic stem cell transplant per institutional standards.","id":"OG002","title":"Leukemia Stem Cells - Transplant"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2 years","title":"Relapse Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of participants"}